Baxter (NYSE:BAX) today touted new data demonstrating survival rate improvements with its Sharesource digital health platform.
Deerfield, Illinois–based Baxter presented data during the American Society of Nephrology’s annual Kidney Week that took place last week, according to a news release.
Baxter designed its Sharesource remote patient management digital health platform for use in helping to manage home-automated peritoneal dialysis (APD). Data showed a survival rate in patients using Sharesource that registered nearly two times higher than those who didn’t use the digital health platform.
Additionally, the randomized controlled trial of 815 kidney patients across 22 hospitals in Mexico demonstrated a prolonged time to an adverse event (AE) and hospitalization with the use of Sharesource.
Sharesource allows healthcare professionals to monitor their patients’ home dialysis treatments and remotely adjust therapy without the need for patients to make unplanned visits to the clinic. Baxter said Sharesource is available in more than 70 countries and has managed more than 32 million treatments to date.
“The study indicates Sharesource’s role in supporting clinically meaningful outcomes that help kidney patients gain access to home dialysis and remain on therapy for as long as possible,” Baxter Renal Care VP of Medical Affairs Peter Rutherford said in the release. “As we move through the COVID-19 pandemic, digital health is demonstrating how it may support healthcare professionals to improve clinical outcomes and allow patients to remain at home with reduced unplanned hospital visits.”